DNA Repair Genes and Acquired Drug Resistance in Candida

念珠菌的 DNA 修复基因和获得性耐药性

基本信息

批准号：
6870246
负责人：
David T. Kirkpatrick
金额：
$ 17.9万
依托单位：
UNIVERSITY OF MINNESOTA
依托单位国家：
美国
项目类别：
财政年份：
2004
资助国家：
美国
起止时间：
2004-04-01 至 2007-03-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/6870246
关键词：
Candida albicans DNA repair antifungal agents drug resistance fungal genetics gene deletion mutation messenger RNA mutant northern blottings phenotype pulsed field gel electrophoresis

项目摘要

DESCRIPTION (provided by applicant): Candida albicans is the most common fungal pathogen of humans. Normally a commensal, candidiasis may result when the host becomes debilitated or immunosuppressed. In hematogenously disseminated infections, mortality can reach 50%, even with treatment using various antifungal drugs. Acquired antifungal drug resistance is becoming a serious clinical problem, but the mechanisms by which resistance develops are unknown. The genetic changes leading to drug resistance may involve mutation, homozygosis, chromosome translocations, and alterations of repeat sequences. We propose to examine the roles of C. albicans homologs of genes known to be involved in a number of DNA repair pathways, to identify those genes that are required for the genomic changes resulting in antifungal drug resistance in Candida. We will construct strains with null mutations in both copies of genes involved in each of the primary DNA repair processes - base excision repair, nucleotide excision repair, mismatch repair and double-strand break repair. We will use a series of assays to characterize the DNA repair activities of each of the deletion mutants. We will also determine the rate at which the various mutant strains acquire resistance to commonly used antifungal agents, and the type of lesions found in the resistant strains, to identify those DNA repair processes having direct roles in drug resistance development in Candida. The results of these experiments will allow us to determine the ways in which antifungal resistance phenotypes arise and suggest targets for combined therapy that would greatly decrease the problem of acquired resistance. Our data may also address the mechanisms underlying the striking genomic instability of C. albicans observed in vivo. Karyotypic rearrangements arise relatively rarely in the laboratory but are very common in clinical isolates. To date, a rigorous analysis of the mechanisms underlying these observations has not been attempted in Candida. Since we expect that we will find altered karyotypes among the drug-resistant mutants we isolate, our proposed experiments will point to some of these mechanisms, providing a solid framework for future work on drug resistance, Candida genome stability, and associated processes.

描述（由申请人提供）：白色念珠菌是人类最常见的真菌病原体。通常，当宿主衰弱或免疫抑制时，可能会导致共生念珠菌病。在血行播散性感染中，即使使用各种抗真菌药物治疗，死亡率仍可达 50%。获得性抗真菌药物耐药性正在成为一个严重的临床问题，但耐药性产生的机制尚不清楚。导致耐药性的遗传变化可能涉及突变、纯合、染色体易位和重复序列的改变。我们建议检查已知参与许多 DNA 修复途径的白色念珠菌同源基因的作用，以确定导致念珠菌抗真菌药物耐药性的基因组变化所需的基因。我们将构建在涉及每个主要 DNA 修复过程（碱基切除修复、核苷酸切除修复、错配修复和双链断裂修复）的两个基因拷贝中均具有无效突变的菌株。我们将使用一系列测定来表征每个缺失突变体的 DNA 修复活性。我们还将确定各种突变菌株对常用抗真菌药物产生耐药性的速率，以及耐药菌株中发现的病变类型，以确定那些在念珠菌耐药性发展中具有直接作用的 DNA 修复过程。这些实验的结果将使我们能够确定抗真菌耐药表型出现的方式，并提出联合治疗的目标，从而大大减少获得性耐药的问题。我们的数据还可以解决体内观察到的白色念珠菌显着基因组不稳定性的机制。核型重排在实验室中相对罕见，但在临床分离株中非常常见。迄今为止，尚未在念珠菌中尝试对这些观察结果背后的机制进行严格分析。由于我们期望在我们分离的耐药突变体中发现改变的核型，因此我们提出的实验将指出其中一些机制，为未来的耐药性、念珠菌基因组稳定性和相关过程的工作提供坚实的框架。